Combined, our in vitro and in vivo data demonstrate that subjecting PTENLOW cancer cells or tumours to clinically relevant doses of IR amplifies chemokine signalling, potentiating autocrine and paracrine signalling throughout the microenvironment that supports the survival of PTEN-deficient cells and facilitates the acquisition of a myeloid-enriched and potentially immunosuppressive microenvironment. Here, PTEN is linked to cancer.